Premium
Front Cover: Antibody–Prodrug Conjugates with KSP Inhibitors and Legumain‐Mediated Metabolite Formation (Chem. Eur. J. 35/2019)
Author(s) -
Lerchen HansGeorg,
StelteLudwig Beatrix,
Berndt Sandra,
Sommer Anette,
Dietz Lisa,
Rebstock AnneSophie,
Johannes Sarah,
Marx Leo,
Jörißen Hannah,
Mahlert Christoph,
Greven Simone
Publication year - 2019
Publication title -
chemistry – a european journal
Language(s) - English
Resource type - Reports
SCImago Journal Rank - 1.687
H-Index - 242
eISSN - 1521-3765
pISSN - 0947-6539
DOI - 10.1002/chem.201901769
Subject(s) - prodrug , metabolite , front cover , conjugate , chemistry , antibody , lysosome , cover (algebra) , active metabolite , pharmacology , biochemistry , enzyme , biology , immunology , mechanical engineering , mathematical analysis , mathematics , engineering
In the lysosome , legumain (LGMN in the picture) is required to release the active KSPi‐metabolite from antibody–prodrug conjugates, in addition to complete antibody degradation. High LGMN expression in solid tumors compared with healthy tissue may lead to drugs with further increased tumor selectivity and lower off‐target toxicity. More information can be found in the Communication by H.‐G. Lerchen et al. on page 8208. The authors thank the graphic designers at The New Atlantic (Cologne) and Jürgen Franz for designing the cover image.